Navigation Links
Mother of Four with Congenital Heart Defect & Biventricular Heart Failure Bridged to Transplant with the SynCardia Total Artificial Heart
Date:7/18/2013

TUCSON, Ariz., July 18, 2013 /PRNewswire/ -- Stacie Sumandig is no stranger to heart problems. Born with a congenital heart defect called coarctation of the aorta, a narrowing of the major artery that carries blood away from the heart to the body, she had her first heart surgery at age 4, and an aortic valve replacement at age 31. But last October, when a virus attacked her aortic valve and destroyed her heart, the news she received at two different hospitals was grim: she probably wouldn't make it through the weekend.

"You can't even process that," said Sumandig. "I'm 40, and I have two kids and two stepkids, and I thought, that is not an option."

Sumandig was transferred to the University of Washington (UW) Medical Center in Seattle, where doctors offered her one final option that hadn't been available at the two previous hospitals: the SynCardia temporary Total Artificial Heart.

"Stacie presented a very difficult problem for us from both a medical and surgical standpoint," said her surgeon, Dr. Nahush Mokadam, co-director of heart transplantation and director of mechanical circulatory support at UW Medical Center. "She had suffered a large heart attack in her right ventricle and had ongoing heart failure in both the left and right sides of her heart (right greater than left). In addition, she had undergone a complex aortic valve reconstruction years prior, but her aorta had separated from her heart by several centimeters, which likely led to a kink in her right coronary artery, causing her massive heart attack.

"I did not think a repeat reconstruction would be tolerated due to her failing heart, so I counseled her on the Total Artificial Heart. It was the only option that would allow me to address the separation of her aorta while supporting her heart function, and provide her with a durable bridge to her eventual heart transplant."

Four days after Sumandig was admitted to UW Medical Center, on Nov. 6, 2012, Dr. Mokadam removed her failing heart and replaced it with the SynCardia Total Artificial Heart.

"It's kind of scary when they first tell you about the Total Artificial Heart, but it's an amazing gift," said Sumandig. "I wouldn't be here without it. The Total Artificial Heart was better than the heart I was born with."

On Dec. 21, 2012, Sumandig was discharged from the hospital to wait for a matching donor heart at home using the Freedom® portable driver, the world's first wearable power supply for the Total Artificial Heart.  

"The Freedom driver gave me a fairly normal life while I was waiting for my donor heart," said Sumandig. "I went shopping. I went on walks with my sister at the park. We had a family gathering, and I played badminton and cornhole. I even went bowling." (See photo)

On May 21, after 196 days of life with the Total Artificial Heart, Sumandig received the call that a matching donor heart had become available. Two days after the transplant, she was breathing on her own and after two more days, she was up walking the hospital hallways. Sumandig was discharged home with her new donor heart on June 6.

"I miss the team at University of Washington a lot," said Sumandig. "I will always have a place in my heart for them. They were so kind, so good, so thorough, and I'm just so thankful that I could be a part of Dr. Mokadam's miracle. I can't thank him enough. Now I'll be able to grow old with my family."

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,100 implants of the Total Artificial Heart, accounting for more than 300 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019
Follow SynCardia on Twitter – http://twitter.com/SynCardia

CONTACT: Don Isaacs, Vice President of Communications, +1-520-955-0660, Disaacs@syncardia.com

 


 


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
2. Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors
3. Hospira Data on European Biosimilar Epoetin, Retacrit, Affirm Treatment Response, Tolerability in Management of Anemia Secondary to Chemotherapy
4. Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
5. Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions
6. Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
7. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
8. This Mothers Day Give The Gift Of A Good Nights Rest
9. Lifelong Antiretroviral Treatment for HIV-Infected Pregnant Women Prevents Infection in Children, Saves Mothers Lives, Study Finds
10. Healthy Mother Announces Formation of The Healthy Mother Foundation
11. Allina Health and Childrens Hospitals and Clinics of Minnesota Celebrate Grand Opening of The Mother Baby Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
(Date:12/6/2016)... -- Diabetes & Obesity Drug Development Pipeline Review, 2016 ... is currently dominated by therapeutics indicated for type 1 ... and the majority of the pipeline, in terms of ... these indications. While products indicated for obesity do not ... large number of these products in the pipeline, with ...
(Date:12/6/2016)... The pen needles market is projected to reach USD ... 2016, growing at a CAGR of 11.2% during the ... years, the pen needles market has witnessed various technological ... for safety injections in the healthcare industry. These advancements ... with an aim to reduce pain, increase comfort, and ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, ... at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of ... acupuncturists to help patients realize their family building goals. Acupuncture helps fertility ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a ... to the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation ... she can for this country. , Nancy attributes her patriotic nature to her WWII ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” ... Day that follows. , “Fred Rides a Train” is the creation of published ... stories since her teen years in Michigan. The "Fred, the Dog" series is her ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... fifth annual Business Architecture Innovation Summit in Reston, VA on March 21-22, 2017. ... will share a range of experiences from a cross-section of industries such as ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home ... is proud to announce new city-specific pages as part of its ambitious website relaunch. ... they often look, first, for local agencies serving their city. The new site has ...
Breaking Medicine News(10 mins):